1. Home
  2. BCYC vs EBS Comparison

BCYC vs EBS Comparison

Compare BCYC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$4.84

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Logo Emergent Biosolutions Inc.

EBS

Emergent Biosolutions Inc.

HOLD

Current Price

$8.00

Market Cap

411.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCYC
EBS
Founded
2009
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.7M
411.1M
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
BCYC
EBS
Price
$4.84
$8.00
Analyst Decision
Buy
Strong Buy
Analyst Count
10
1
Target Price
$13.90
$12.00
AVG Volume (30 Days)
422.2K
638.8K
Earning Date
05-01-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
125.83
EPS
N/A
0.93
Revenue
N/A
$742,900,000.00
Revenue This Year
N/A
$1.29
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.66
Revenue Growth
N/A
N/A
52 Week Low
$4.24
$4.71
52 Week High
$9.55
$14.06

Technical Indicators

Market Signals
Indicator
BCYC
EBS
Relative Strength Index (RSI) 45.27 43.26
Support Level $4.24 $7.73
Resistance Level $5.41 $8.54
Average True Range (ATR) 0.20 0.34
MACD 0.01 0.02
Stochastic Oscillator 15.04 21.09

Price Performance

Historical Comparison
BCYC
EBS

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

About EBS Emergent Biosolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Share on Social Networks: